Kidney Transplant Recipients and Cancer: Understanding Rejection Risks
Author Information
Author(s): Erol Demir, Mevlut Tamer Dincer, Cebrail Karaca, Cansu Erel, Latif Karahan, Aslihan Pekmezci, Sinan Trabulus, Nurhan Seyahi, Aydin Turkmen
Primary Institution: Koç University Hospital, Istanbul, Türkiye
Hypothesis
Does de novo malignancy heighten the risk of rejection in kidney transplant recipients?
Conclusion
Kidney transplant recipients with de novo malignancies have a lower rate of allograft rejection compared to those without malignancies.
Supporting Evidence
- 267 kidney transplant recipients with malignancies were included in the study.
- The allograft rejection rates were lower in the malignancy group compared to the control group.
- Chemotherapy and older age were associated with reduced risk of allograft rejection.
- Overall mortality was higher in the malignancy group, but not statistically significant.
- Death-censored allograft loss was similar between the malignancy and control groups.
Takeaway
This study found that kidney transplant patients who get new cancers are less likely to have their transplanted kidney rejected than those who don't have cancer.
Methodology
This retrospective case-control study included adult kidney transplant patients diagnosed with de novo malignancies from 1986 to 2020, matched with controls without malignancies.
Potential Biases
The absence of monitoring for anti-HLA antibodies may have led to underdiagnosis of subclinical rejections.
Limitations
Selection biases may have influenced treatment modalities due to the retrospective nature of the study.
Participant Demographics
Median age of participants was 60 years, with 66.3% being male.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website